AGENUS INC
NASDAQ: AGEN (Agenus Inc.)
Kemas kini terakhir: 10 jam lalu3.10
0.12 (4.03%)
| Penutupan Terdahulu | 2.98 |
| Buka | 3.02 |
| Jumlah Dagangan | 310,657 |
| Purata Dagangan (3B) | 651,556 |
| Modal Pasaran | 112,039,208 |
| Harga / Pendapatan (P/E Ke hadapan) | 5.13 |
| Harga / Jualan (P/S) | 0.750 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 16 Mar 2026 |
| Margin Keuntungan | -191.50% |
| Margin Operasi (TTM) | -55.31% |
| EPS Cair (TTM) | 29.61 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -14.10% |
| Nisbah Semasa (MRQ) | 0.110 |
| Aliran Tunai Operasi (OCF TTM) | -145.74 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -114.08 M |
| Pulangan Atas Aset (ROA TTM) | -28.70% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Agenus Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | 0.13 |
|
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.93% |
| % Dimiliki oleh Institusi | 33.95% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Panagora Asset Management Inc | 31 Dec 2025 | 163,148 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |